Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country.
This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.

A - B - C - D - E - F - G - H I - J - K - L - M N - O - P - Q - R - S T - U - V - W - X - Y - Z

Clinical study results Sanofi pharma, including Sanofi Genzyme – Letter P

GENERIC NAME

TRADE NAME

CONDITION

STUDY CODE

STUDY NAME

ACCESS TO STUDY / PROTOCOL

ACCESS TO RESULTS

PAN PI3K INHIBITOR

Not marketed

Endometrial Neoplasms

ARD11436

NA

EudraCT: 2009-016707-30

PAN PI3K INHIBITOR

Not marketed

Breast Neoplasms

ARD11437

NA

NCT01082068

PAN PI3K INHIBITOR

Not marketed

Breast Neoplasms

ARD11439

NA

EudraCT: 2009-016862-10

PAN PI3K INHIBITOR

Not marketed

Solid Tumors

TCD11742

NA

NCT01357330

PAN PI3K INHIBITOR

Not marketed

Neoplasms

TED12863

NA

NCT01943838

PAN PI3K INHIBITOR

Not marketed

Solid Tumors

TED11883

NA

NCT01392924

PAN PI3K AND MTOR INHIBITOR

Not marketed

Lymphoma or Leukemia

ARD12130

NA

EudraCT: 2011-001616-57

PAN PI3K AND MTOR INHIBITOR

Not marketed

Indolent Lymphoma

TCD12012

NA

NCT01410513

PAN PI3K AND MTOR INHIBITOR

Not marketed

Glioblastoma

TED11605

NA

NCT01240460

PAN PI3K AND MTOR INHIBITOR

Not marketed

Neoplasms

TED12471

NA

NCT01596270

PAN PI3K AND MTOR INHIBITOR

Not marketed

Neoplasm Malignant

TED12414

NA

NCT01587040

PARACETAMOL

Doliprane

Pain

PARAC_L_00859

NA

NCT00434681

PHOSPHATIDYL CHOLINE

Essentiale

Liver Disease

CHOLIL06301

EPLID

NCT02517385

PI3K-B INHIBITOR

Not marketed

Solid Tumors, Lymphoma

TCD12739

NA

NCT01673737

PLERIXAFOR

Mozobil

Non-Hodgkin's Lymphoma

ACT12781

NA

NCT02221492

PLERIXAFOR

Mozobil

Multiple Myeloma

ACT13710

NA

NCT02221479

PLERIXAFOR

Not marketed

Renal Impairment

AMD31001101

NA

NCT00445302

PLERIXAFOR

Mozobil

Multiple Myeloma or Non-Hodgkin's Lyjmphoma

AMD3100-2104

NA

NCT00322387

PLERIXAFOR

Mozobil

Multiple Myeloma or Non-Hodgkin's Lyjmphoma

AMD3100-2105

NA

NCT00322491

PLERIXAFOR

Not marketed

Hodgkin's Disease

AMD3100-2106

NA

NCT00396201

PLERIXAFOR

Mozobil

Multiple Myeloma

AMD3100-2108

NA

NCT00396383

PLERIXAFOR

Mozobil

Multiple Myeloma or Non-Hodgkin's Lyjmphoma

AMD3100-2109

NA

NCT00395967

PLERIXAFOR

Not marketed

Transplantation

AMD31002112

NA

NCT00396331

PLERIXAFOR

Mozobil

Non-Hodgkin's Lymphoma or Hodgkin's Disease

AMD31002113

NA

NCT00444912

PLERIXAFOR

Mozobil

Non-Hodgkin's Lymphoma

AMD31003101

NA

NCT00103610

PLERIXAFOR

Mozobil

Multiple Myeloma

AMD31003102

NA

NCT00103662

PLERIXAFOR

Mozobil

Multiple Myeloma or Non-Hodgkin's Lyjmphoma

AMD3100C201

NA

NCT00396266

PLERIXAFOR

Mozobil

Multiple Myeloma or Non-Hodgkin's Lyjmphoma

AMD3100EU21

NA

NCT00322842

PLERIXAFOR

Mozobil

Multiple Myeloma

ARD12858-MOZ23510

NA

EudraCT: 2011-004783-30

PLERIXAFOR

Not marketed

Solid Tumors

MOZ15609-DFI12860

MOZAIC

EudraCT: 2010-019340-40

PLERIXAFOR

Mozobil

Non-Hodgkin's Lymphoma

EFC12482

NA

NCT01767714

PLERIXAFOR

Mozobil

Non-Hodgkin's Lymphoma

MOZ11809

NA

NCT01164475

PRISTINAMYCIN

Pyostacin

Infection

PRIST_L_01683

NA

NCT00393744

PROSTAGLANDINE E2 RECEPTOR ANGONIST

Not marketed

Open Angle Glaucoma or Ccular Hypertension

TDR13459

NA

NCT02531152

RIPK1 INHIBITOR

Not marketed

Amyotrophic Lateral Sclerosis

TDR16536

NA

NCT03757351


References:
*These study results were previously posted on GenzymeClinicalResearch.com
**This link replaces the same summary that was previously posted